BERG Enters Into an Agreement With Sanofi Pasteur to Identify Biomarkers of Flu Vaccine Performance

Molecular Data Will be Analyzed Using Artificial Intelligence Through BERG’s Interrogative Biology® Platform to Better Understand Influenza Vaccination Response BOSTON — BERG, a biopharmaceutical company that merges biology with technology, today announced a new research effort with Sanofi Pasteur, the influenza vaccine global leader. Under this agreement, BERG will generate and model data using BERG’s…

BERG Honored with Partner in Progress Award from DEBRA of America at Annual Benefit for Rare Disease Epidermolysis Bullosa

BERG’s BPM 31510 Drug Candidate Recognized as Potential Novel Therapy for Treating Rare Disease BOSTON — BERG, a biopharmaceutical company that merges biology with technology, today announced that the Company was honored with a Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America (debra of America). The award recognizes the Company’s…

BERG Broadens Relationship with Department Of Defense (DoD) Center For Prostate Disease Research with New Predictive Biomarker Test for Prostate Cancer

New Clinical Evidence Guided by Artificial Intelligence that Could Significantly Enhance Prostate Cancer Detection and Reduce Over-Diagnosis and Unnecessary Treatments in Benign Prostate Hyperplasia Patients arises from Research Collaboration with BERG and the Center for Prostate Disease (CPDR) in the Department of Surgery, Uniformed Services University (USU) BOSTON — BERG, a biopharmaceutical company that merges…

BERG Presents Key Clinical Data at ESMO 2017 on BPM 31510 for Advanced Pancreatic Cancer Patients and BPM 31543 for Preventing Hair-Loss in Patients Treated With Chemotherapy

New Data Show Promising Results and Support Continued Clinical Development,Highlights Success of Interrogative Biology Platform to Advance Potential New Treatment Options for Cancer Patients BOSTON, Sept. 11, 2017 — BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced two poster presentations showing promising clinical data that were unveiled…

BERG Forms Research Collaboration with AstraZeneca to Identify New Therapeutic Targets to Treat Neurological Disorders such as Parkinson’s Disease

Collaboration to Focus on a Disease Target in Parkinson’s Disease With Berg’s Interrogative Biology® Technology BOSTON, Aug. 28, 2017 – BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced a research collaboration with AstraZeneca to identify and evaluate novel targets and therapeutics to treat neurological disorders such…

BERG Announces New Partnership with debra of America to Tackle Epidermolysis Bullosa, a Rare Genetic Tissue Disorder

Biopharmaceutical and Patient Advocacy Group Join Forces to Galvanize the Disease Community and Advance Treatment Research BOSTON, May 15, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced they have entered into a partnership agreement with The Dystrophic Epidermolysis Bullosa Research Association of America (debra of America)…

BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Multiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel

BOSTON, April 3, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced seven poster presentations showing promising preclinical data. This data reflects the impact of BERG’s leading product candidate, BPM 31510, to augment immune responses and potentially improve outcomes of patients suffering from glioblastoma multiforme (GBM), pancreatic…

New Data Published in Nature Medicine from Joslin Diabetes Center Demonstrates the Importance of Interrogating Human Biology

BOSTON, March 27, 2017— BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that the company’s Interrogative Biology® Platform contributed to the discovery of new data using a cold-induced model to promote thermogenesis and facilitate brown fat metabolism. Joslin Diabetes Center led the investigation with BERG providing its Interrogative Biology® platform…

BERG Initiates Phase I/II Monotherapy Trial of BPM 31510-IV in Patients with Glioblastoma Multiforme (GBM)

BOSTON, Feb. 15, 2017 — BERG LLC, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase I/II monotherapy clinical trial for its drug candidate BPM 31510-IV for the potential treatment of glioblastoma multiforme. The compound was guided in development by BERG’s unique AI-based Interrogative Biology® platform that combines…

BERG Enters into Multi-Year Agreement with BD for Next-Generation Analytics in Healthcare IT

Leading Health Companies Combine Health IT Expertise to Advance Patient Health Outcomes BOSTON, Jan. 12, 2017 — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, announced a multi-year agreement between BERG Analytics, a division of BERG, and BD’s MedMined™ solution.  This new collaboration will leverage the combined healthcare IT expertise of BD…
1 2 3